Physician profile
Angela Hardwick
NPI 1497964498
$186,566.88
in general payments reported to CMS, 2019-2025
13 companies · $47K in 2025
The $47K reported for 2025 was more than what 96% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $5,990 · 2021: $5,394 · 2022: $20K · 2023: $51K · 2024: $44K · 2025: $47K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $119K · Travel and Lodging: $13K · Food and Beverage: $6,024 · Consulting Fee: $2,650 · Honoraria: $1,760 · Education: $335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $118,673.57 |
| Travel and Lodging | $12,627.44 |
| Food and Beverage | $6,023.82 |
| Consulting Fee | $2,650.00 |
| Honoraria | $1,760.00 |
| Education | $334.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $100,190.17 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Acadia Pharmaceuticals INC | $76,388.24 | 2021-2025 | Nuplazid |
| Amneal Pharmaceuticals LLC | $3,784.53 | 2019-2025 | Crexont, Rytary |
| Medtronic, INC. | $2,253.45 | 2023-2025 | Activa PC, Percept PC Brainsense, Sensight |
| Mdd US Operations, LLC | $1,793.68 | 2025 | Gocovri |
| Boston Scientific Corporation | $834.58 | 2019 | |
| Insightec,INC | $603.41 | 2021 | |
| Sunovion Pharmaceuticals INC. | $378.11 | 2019-2020 | |
| Abbvie INC. | $231.02 | 2019-2025 | |
| Adamas Pharmaceuticals, INC. | $48.75 | 2019 | |
| Lundbeck LLC | $23.17 | 2023 | Rexulti |
| Neurocrine Biosciences, INC. | $20.00 | 2025 | |
| Allergan, INC. | $17.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Hardwick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.